Loading provider…
Loading provider…
Internal Medicine Physician in Houston, TX
NPI: 1003901612Primary Employer
Physicians Referral Service
mdanderson.org
HQ Phone
Get M.D. Jan's Phone Numberphone_androidMobile
Get M.D. Jan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
FL State Medical License
2021
TX State Medical License
2011 - 2027
OK State Medical License
2020 - 2021
WV State Medical License
2009 - 2020
Freiburg University Hospital
Fellowship • Instructor
1999 - 2005
Residency • 1995 - 1996
1995 - 1996
University of California
Fellowship • 1996 - 1999
1996 - 1999
Albert Ludwigs University Faculty of Medicine
Medical School
Until 1994
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 186 | 472 |
| 2 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 33 | 34 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 33 | 175 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 32 | 231 |
| 5 | 99442Physician telephone patient service, 11-20 minutes of medical discussion | 22 | 40 |
Fishing and risk along the Savannah River: possible intervention.
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: J Toxicol Environ Health A
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Curr Hematol Malig Rep
Authors: Susan O'Brien, Ian Flinn, John Byrd, Richard Furman, James Dean, Kristie Blum, William Wierda, Nyla Heerema
Journal: Clin Cancer Res
Publication Date: 2020-03-24
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Acalabrutinib, BIOLOGICAL: Obinutuzumab
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Zanubrutinib, BIOLOGICAL: Rituximab
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: M.D. Anderson Cancer Center
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, DRUG: Ibrutinib